生长抑素受体 (SSTR) 靶向 PET 成像已成为评估高分化神经内分泌肿瘤 (NET) 患者的常用方法。 SSTR 报告和数据系统 (SSTR-RADS) 1.0 版提供了一种根据 NET 受累的可能性将病变从 1 到 5 进行分类的方法，包括 SSTR-RADS-3A（软组织）和 SSTR-RADS-3B（骨） ) 病变是那些暗示但没有明确的 NET 受累的病变。本研究的目的是评估 68Ga-DOTATATE PET/MR 成像数据预测不确定 SSTR-RADS-3A 和 3B 病变结果的能力。NET 患有不确定 SSTR-RADS-3A 或 SSTR-RADS-3B 病变的患者对 2020 年 4 月至 2023 年 8 月接受 68Ga-DOTATATE PET/MR 成像的患者进行回顾性评估。所有患者均接受随访至 2023 年 12 月（中位时间 17 个月；（3-31 个月）），影像随访或活检结果最终用于将病变分类为恶性或良性。测量病灶最大标准化摄取值 (SUVmax) 以及最小和平均表观扩散系数 (ADCmin 和 ADCmean) 值，并评估其与随访结果的相关性。总共，来自 22 名患者的 33 个不确定的 SSTR-RADS-3 病灶（ 19 SSTR-RADS-3A 和 14 SSTR-RADS-3B）是根据基线 68Ga-DOTATATE PET/MR 结果确定的。在随访过程中，发现其中 16 个病变 (48.5%) 表现出真正的 NET 阳性，包括 9 个 SSTR-RADS-3A 和 7 个 SSTR-RADS-3B 病变。对于 SSTR-RADS-3A 淋巴结，直径大于 0.7 cm 且 ADCmin 为 779 × 10-6mm2/s 或更低被认为更有可能与转移性病灶相关。比较转移性和非转移性 SSTR-RADS-3B 骨病变时，ADCmin 和 ADCmean 存在显着差异 (P < 0.05)，这些参数具有较高的预测能力 (AUC = 0.94，AUC = 0.86)。直径和 ADCmin可以帮助准确识别与 SSTR-RADS-3A 淋巴结相关的病变性质，而 ADCmin 和 ADCmean 值可以准确解释 SSTR-RADS-3B 骨病变。© 2024。作者。

Somatostatin receptor (SSTR)-targeted PET imaging has emerged as a common approach to evaluating those patients with well-differentiated neuroendocrine tumors (NETs). The SSTR reporting and data system (SSTR-RADS) version 1.0 provides a means of categorizing lesions from 1 to 5 according to the likelihood of NET involvement, with SSTR-RADS-3A (soft-tissue) and SSTR-RADS-3B (bone) lesions being those suggestive of but without definitive NET involvement. The goal of the present study was to assess the ability of 68Ga-DOTATATE PET/MR imaging data to predict outcomes for indeterminate SSTR-RADS-3A and 3B lesions.NET patients with indeterminate SSTR-RADS-3A or SSTR-RADS-3B lesions who underwent 68Ga-DOTATATE PET/MR imaging from April 2020 through August 2023 were retrospectively evaluated. All patients underwent follow-up through December 2023 (median, 17 months; (3-31 months)), with imaging follow-up or biopsy findings ultimately being used to classify lesions as malignant or benign. Lesion maximum standardized uptake value (SUVmax) along with minimum and mean apparent diffusion coefficient (ADCmin and ADCmean) values were measured and assessed for correlations with outcomes on follow-up.In total, 33 indeterminate SSTR-RADS-3 lesions from 22 patients (19 SSTR-RADS-3A and 14 SSTR-RADS-3B) were identified based upon baseline 68Ga-DOTATATE PET/MR findings. Over the course of follow-up, 16 of these lesions (48.5%) were found to exhibit true NET positivity, including 9 SSTR-RADS-3A and 7 SSTR-RADS-3B lesions. For SSTR-RADS-3A lymph nodes, a diameter larger than 0.7 cm and an ADCmin of 779 × 10-6mm2/s or lower were identified as being more likely to be associated with metastatic lesions. Significant differences in ADCmin and ADCmean were identified when comparing metastatic and non-metastatic SSTR-RADS-3B bone lesions (P < 0.05), with these parameters offering a high predictive ability (AUC = 0.94, AUC = 0.86).Both diameter and ADCmin can aid in the accurate identification of the nature of lesions associated with SSTR-RADS-3A lymph nodes, whereas ADCmin and ADCmean values can inform the accurate interpretation of SSTR-RADS-3B bone lesions.© 2024. The Author(s).